A Study to Learn How Different Amounts of the Study Medicine Called PF-08642534 Are Tolerated and Act in the Body of People Who Have Obesity

NCT07731139 · tracked via the Priya Life Science USA tracker

Sponsor

Pfizer

Phase

Phase 1

Started

2026-07-28

Last updated

2026-07-28

Condition(s) studied

Obesity

Investigational drug(s) / intervention(s)

PF-08642534Placebo

PF-08642534: Participants will receive PF-08642534 QD (once a day)

Placebo: Participants will receive matching placebo QD (once a day)

Study summary

This study will look at a study drug called PF-08642534 in people with obesity (have too much body weight) to see: if participants can take different amounts (doses) of the study drug in a safe way and how adults with obesity tolerate it, and how the body handles the study drug (for example, how the study drug is absorbed and removed from the body).

People who want to join the study will first go through a screening period of up to 4 weeks. Doctors will check if each person meets the study conditions, including age, body weight, and general health. People with certain medical conditions will not be able to take part in the study.

Eligibility

Sex

ALL

Min age

18 Years

Max age

70 Years

Healthy volunteers

Inclusion: * Body mass index (BMI) ≥30.0 and ≤40.0 kg/m², and with stable body weight prior to screening. * Participants are generally otherwise healthy but may have mild chronic conditions (eg, dyslipidemia or hypertension) Exclusion: \- Individuals with diabetes, significant cardiovascular, hepatic, renal, gastrointestinal, or psychiatric disorders, or conditions that may affect drug absorption or metabolism, are not eligible to participate.

Primary outcome measure(s)

Incidence of treatment emergent adverse events (TEAE) — Baseline up to 8 weeks after last dose

Trial sites (1)

Facility	City	Region	Status
Orange County Research Center	Lake Forest	California

More Pfizer trials in the USA

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors Active, not recruiting

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients Recruiting

Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy Active, not recruiting

A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata Recruiting

Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania Active, not recruiting

Other trials for the same condition

A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity Active, not recruiting

A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight Active, not recruiting

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity Recruiting

A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy Enrolling by invitation

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07731139 on ClinicalTrials.gov ↗ ← All trials in the USA